CMA clarifies cooperation on combination therapies to speed up patient access to vital treatments
Reviewed The Competition and Markets Authority (CMA) has today issued a statement clarifying that certain types of engagements between competing drug firms working on 'combination therapies' will not be prioritized for investigation – making it easier for drug firms to work together to develop vital treatments for use in the NHS. The CMA's statement comes in response to concerns that […]
Continue reading »